Advertisement

Neuroscience and Behavioral Physiology

, Volume 44, Issue 5, pp 517–519 | Cite as

Cognitive Impairments in Patients with Multiple Sclerosis: Correlations Between Neuropsychological, Neurophysiological, and Neuroimaging Parameters

  • V. M. Alifirova
  • N. F. Musina
Article

The aim of this study was to assess the neuropsychological status of patients and their P300 cognitive evoked potentials and to attempt to evaluate the clinical significance of cerebral atrophy in multiple sclerosis (MS). Neuropsychological studies were performed in 109 patients with MS. Cognitive functions were evaluated using the mini-mental state examination (MMSE), the frontal assessment battery (FAB), the A. R. Luriya method, and P300 cognitive evoked potentials; MRI data from 71 patients were also analyzed. The results obtained from these studies led to the conclusion that changes in status and cognitive function, disease activity, and the severity of cerebral atrophy are correlated.

Keywords

multiple sclerosis cognitive impairments neuropsychological investigations P300 cognitive evoked potentials cerebral atrophy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    T. G. Alekseeva, A. N. Boiko, Yu. L. Razhba, et al., “A complex approach to assessing the cognitive and emotional-personality domains in multiple sclerosis patients,” Zh. Nevrol. Psikhiat., Rass. Skleroz, 102, 20–25 (2002).Google Scholar
  2. 2.
    A. N. Boiko, S. V. Petrov, E. I. Gusev, and V. A. Nesterova, “Mechanism of development of the neurodegenerative process in multiple sclerosis – the neuroprotective effect of ®-interferon formulations today and neurotrophic factors tomorrow,” Zh. Nevrol. Psikhiat., Rass. Skleroz, 103, No. 2, 83–90 (2003).Google Scholar
  3. 3.
    V. V. Gnezditskii, Evoked Brain Potentials in Clinical Practice [in Russian], Medpress-inform, Moscow (2003).Google Scholar
  4. 4.
    T. L. Demina, M. V. Davydovskaya, T. D. Zhuchenko, et al., “Studies of glatiramer acetate (Copaxone) in the treatment of patients with multiple sclerosis. Experience at the Multiple Sclerosis Center,” Zh. Nevrol. Psikhiat., Rass. Skleroz, 103, No. 2, 91–97 (2003).Google Scholar
  5. 5.
    O. A. Khondkarian, I. A. Zavalishin, and O. M. Nevskaya, Multiple Sclerosis, Meditsina, Moscow (1987).Google Scholar
  6. 6.
    M. P. Amato and V. Zipoli, “Clinical management of cognitive impairment in multiple sclerosis: a review of current evidence,” Multiple Sclerosis, 10, 73–83 (2003).Google Scholar
  7. 7.
    J. C. Brassington and N. V. Marsh, “Neuropsychological aspects of multiple sclerosis,” Neuropsychol. Rev., 8, 43–77 (1998).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Neurology and NeurosurgerySiberian State Medical UniversityTomskRussia

Personalised recommendations